Flagship takes a rare knock as cell replacement startup based on Bob Langer tech gets slapped with clinical hold
In the age of Moderna, it’s rare to see storied startup machine Flagship Pioneering take a loss — let alone for a team backed by research from Bob Langer’s lab. Nevertheless, a great pedigree doesn’t mean there won’t be setbacks, a lesson an older Flagship brand is finding out the hard way.
The FDA has placed a clinical hold on Sigilon Therapeutics’ non-viral cell therapy for hemophilia A, dubbed SIG-001, after a patient in a Phase I/II trial reported a case of Factor VIII inhibition, the biotech said Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 128,800+ biopharma pros reading Endpoints daily — and it's free.